These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 927209)

  • 1. One method for the systematic evaluation of adverse drug experience data within a pharmaceutical firm.
    Westlin WF; Cuddihy RV; Bursik RJ; Seifert BG; Koelle JG
    Methods Inf Med; 1977 Oct; 16(4):240-70. PubMed ID: 927209
    [No Abstract]   [Full Text] [Related]  

  • 2. CONTROL OF DRUG TOXICITY IN THE UNITED STATES OF AMERICA.
    WESTON JK; WESTON K
    Practitioner; 1965 Jan; 194():16-21. PubMed ID: 14259685
    [No Abstract]   [Full Text] [Related]  

  • 3. Experience in monitoring drug reactions in outpatients. The Kaiser-Permanente Drug Monitoring System.
    Friedman GD; Collen MF; Harris LE; Van Brunt EE; Davis LS
    JAMA; 1971 Aug; 217(5):567-72. PubMed ID: 5109088
    [No Abstract]   [Full Text] [Related]  

  • 4. The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy.
    Simmons HE
    Int J Health Serv; 1974; 4(1):95-107. PubMed ID: 4829901
    [No Abstract]   [Full Text] [Related]  

  • 5. US FDA seeks more pharmaceutical industry cash.
    Zwillich T
    Lancet; 2007 Feb; 369(9559):357. PubMed ID: 17283497
    [No Abstract]   [Full Text] [Related]  

  • 6. ADVERSE DRUG REACTION REPORTING AND THE RELATED ESTABLISHMENT OF A REGISTRY OF TISSUE REACTIONS TO DRUGS.
    WESTON JK
    Med Ann Dist Columbia; 1965 Aug; 34():380-2. PubMed ID: 14338452
    [No Abstract]   [Full Text] [Related]  

  • 7. The current status of guidelines for clinical research from the viewpoint of the pharmaceutical industry.
    Dixon RB
    J Clin Pharmacol; 1977; 17(11-12):691-6. PubMed ID: 925189
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmaceutical drugs-the good and the not so good: together, we can make it better.
    Campbell AW
    Altern Ther Health Med; 2014; 20(1):9-11. PubMed ID: 24445351
    [No Abstract]   [Full Text] [Related]  

  • 9. Modification of a management information system software package to process drug reaction data.
    Cuddihy RV; Ring WS; Augustine NF
    Methods Inf Med; 1971 Jan; 10(1):9-18. PubMed ID: 5154765
    [No Abstract]   [Full Text] [Related]  

  • 10. Restoring confidence in the pharmaceutical industry.
    Bauchner H; Fontanarosa PB
    JAMA; 2013 Feb; 309(6):607-9. PubMed ID: 23403686
    [No Abstract]   [Full Text] [Related]  

  • 11. Drugs on the market.
    JAMA; 1970 Feb; 211(7):1177. PubMed ID: 5466970
    [No Abstract]   [Full Text] [Related]  

  • 12. Reliability factors in adverse drug reaction reporting.
    Marlin RL
    Methods Inf Med; 1981 Jul; 20(3):157-62. PubMed ID: 7278693
    [No Abstract]   [Full Text] [Related]  

  • 13. A perspective on US drug reimportation.
    Choudhry NK; Detsky AS
    JAMA; 2005 Jan; 293(3):358-62. PubMed ID: 15657329
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic implications of the drug lag.
    Wardell WM
    Clin Pharmacol Ther; 1974 Jan; 15(1):73-96. PubMed ID: 4150345
    [No Abstract]   [Full Text] [Related]  

  • 15. Chirality.
    Lancet; 1990 Nov; 336(8723):1100-1. PubMed ID: 1977984
    [No Abstract]   [Full Text] [Related]  

  • 16. US consumer group criticizes proposal to allow drug makers to challenge safety information.
    McCarthy M
    BMJ; 2015 Mar; 350():h1514. PubMed ID: 25784706
    [No Abstract]   [Full Text] [Related]  

  • 17. The marketing of a drug.
    Wolfe SM
    Health Med; 1982; 1(2):31-2. PubMed ID: 10257087
    [No Abstract]   [Full Text] [Related]  

  • 18. Plans to reduce drug risks examined.
    Young D
    Am J Health Syst Pharm; 2007 Aug; 64(15):1568, 1574, 1578. PubMed ID: 17646555
    [No Abstract]   [Full Text] [Related]  

  • 19. Program seeks to enlist physicians to flag questionable promotion of drugs.
    Mitka M
    JAMA; 2010 Jul; 304(1):28-9. PubMed ID: 20606140
    [No Abstract]   [Full Text] [Related]  

  • 20. The HEALTH Act's FDA defense to punitive damages: a gift to drug makers or to the public?
    Levy E
    Fordham Law Rev; 2006 Mar; 74(4):2425-60. PubMed ID: 17115481
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.